Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
4,434
Employees4,434
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
4,434
Employees4,434

NTRA Key Statistics

Market cap
27.40B
Market cap27.40B
Price-Earnings ratio
-102.56
Price-Earnings ratio-102.56
Dividend yield
Dividend yield
Average volume
1.12M
Average volume1.12M
High today
$198.99
High today$198.99
Low today
$191.75
Low today$191.75
Open price
$196.77
Open price$196.77
Volume
1.08M
Volume1.08M
52 Week high
$198.99
52 Week high$198.99
52 Week low
$117.27
52 Week low$117.27

NTRA News

TipRanks 9h
Natera’s Strong Position in MRD Market Bolstered by Signatera’s Impact and Potential FDA Approval

In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Natera, with a price target of $200.00. Elevate Your Investing...

TipRanks 1d
Natera’s Oncology Advancements and Market Potential Drive Buy Rating

Mark Massaro, an analyst from BTIG, reiterated the Buy rating on Natera. The associated price target was raised to $210.00. Elevate Your Investing Strategy: Tak...

TipRanks 1d
Natera price target raised to $210 from $200 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on Natera (NTRA) to $2 10 from $200 and keeps a Buy rating on the shares. The firm is positive on Nater...

Analyst ratings

90%

of 21 ratings
Buy
90.5%
Hold
4.8%
Sell
4.8%

More NTRA News

Simply Wall St 2d
Is Natera’s Rally Justified After Soaring 58.5% on Genetic Testing Breakthroughs?

Natera stock has captured a lot of attention lately and for good reason. If you’re holding shares or considering jumping in, you’ve probably noticed the numbers...

Is Natera’s Rally Justified After Soaring 58.5% on Genetic Testing Breakthroughs?
Nasdaq 5d
Natera : Phase 3 Trial Results Show Signatera-Guided Therapy Improves Survival In Bladder Cancer

(RTTNews) - Natera Inc. (NTRA) announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC)....

Natera : Phase 3 Trial Results Show Signatera-Guided Therapy Improves Survival In Bladder Cancer
Simply Wall St 5d
Does Natera's MRD Platform Recognition Signal Strengthening Competitive Position in Precision Oncology?

Natera, Inc. recently presented significant clinical data at the ESMO Congress 2025 in Berlin and was recognized by Fast Company for its Signatera molecular res...

Does Natera's MRD Platform Recognition Signal Strengthening Competitive Position in Precision Oncology?
Simply Wall St 6d
Natera Valuation Spotlight: Fast Company Honors Spark Fresh Focus on Growth and Innovation

Natera (NTRA) just landed on Fast Company’s 2025 Next Big Things in Tech list, recognized for its Signatera molecular residual disease test for cancer. This typ...

Natera Valuation Spotlight: Fast Company Honors Spark Fresh Focus on Growth and Innovation

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.